Skip to content
Company Terminals IPO Intel Calculators Gold Desk Research Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus

Dr Reddy's Laboratories

DRREDDY · Biotechnology & Drugs · INE089A01031

Analyst mean 2.97 · 38 analysts · 47% bullish
₹1,142.30
Close 2026-07-31 · Balanced risk

Reading the Statements forensic interpretation

What the numbers mean when read together — computed from the filings, not a score.

Operating cash flow backs the profit

Operating cash flow is 178% of trailing profit — the earnings are converting to cash, not just accruals.

Full read

Last operating cash flow ₹5,674 cr against trailing net profit ₹3,184 cr. A ratio at or above ~0.9 means reported profit is showing up as real cash.

Net margin compressing

Net margin has narrowed from 16.4% to 5.4% year-on-year — profitability per rupee of sales is shrinking.

Full read

Quarter net margin 5.4% vs 16.4% four quarters earlier. Sustained compression signals pricing pressure, cost inflation, or mix deterioration.

Generates free cash

Free cash flow is positive and consistent — the business funds itself after capex.

Full read

Latest free cash flow ₹2,004 cr. Negative in only 0 of 12 years. A self-funding business needs less external capital and dilutes less.

Borrowing while holding investments

Borrowings rose 286% over two years while the company also carries ₹5,285 cr in investments. Why borrow at interest while parking money elsewhere is a fair question.

Full read

Borrowings moved to ₹7,734 cr from ₹2,002 cr. Simultaneous large investments can be legitimate treasury management, or a sign that reported cash is not freely available.

Price & Valuation 10-year, split-adjusted

Markers show corporate actions (splits, bonus, dividends). Prices are split-adjusted so the series is continuous.

Valuation & Quality

Valuation
P/E (TTM) 35.1x
P/B 2.5x
P/S 2.85x
P/FCF 81x
Dividend Yield 0.7%
Leverage
Debt / Equity conservative 0.2
Payout Ratio 20.7%
Returns & Margins
Operating Margin (TTM) 9.1%
Net Margin (TTM) 9.6%
Return on Equity 16.7%
Implied Growth (Graham) growth the market is pricing in 13.3%
Rule of 40 3.6
Growth -5.5% + Margin 9.1% — below 40

Ownership & Skin in the Game

Promoter26.64% ▲ 0.01
FII20.67%
DII
Mutual Funds13.16%

Quarterly Financials ₹ cr

MetricSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue8,0388,3818,5288,5728,8288,7537,5468,100
Expenses5,9626,1086,5306,3986,8186,8667,1647,240
Other Income314154528290330271480356
Depreciation397471455476505521557537
Profit before tax1,9171,8742,0051,9051,7451,543200553
Net Profit1,3421,4041,5871,4101,3371,190221436
EPS15.0516.9419.0916.9916.1414.502.655.32

Balance Sheet ₹ cr, annual

ItemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital838383838384
Reserves17,55819,12923,20328,17133,46637,808
Borrowings3,0313,3841,3472,0024,6777,734
Fixed Assets8,2068,1229,21910,42618,22622,063
CWIP1,5651,2931,0301,4192,4661,460
Investments2,2122,6164,9864,9304,0515,285
Total Assets26,58829,74632,20938,78048,02356,577
DISCLAIMER: FinMinutes is a financial data and analytics platform, not a SEBI-registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.